Study S000280

A Multicenter, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naïve Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy

ClinicalTrials.gov record

Registration

Registration: NCT00755287
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 1072
Start: 2008-11
Primary completion: 2010-12
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:insulin glargine; DRUG:metformin; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2008-001855-23; NIH:2008

Registered primary outcomes

Absolute change from baseline in HbA1c [24 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021623	Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial. Nauck M, Diabetic medicine : a journal of the British Diabetic Association	2013	Randomized trial	PMID 22937895 DOI	cites ClinicalTrials.gov:NCT00755287; registry reference DERIVED:22937895